Imiquimod-d9

• Description :

  Imiquimod-d9 is deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19[1][2].

• CAS Number :

  [2712126-48-0]

• Product Name Alternative :

  R 837-d9

• UNSPSC :

  12352005

• Hazard Statement :

  H302+H312+H332-H315-H319-H335

• Target :

  Autophagy; HSV; Isotope-Labeled Compounds; SARS-CoV; Toll-like Receptor (TLR)

• Type :

  Isotope-Labeled Compounds

• Related Pathways :

  Anti-infection; Autophagy; Immunology/Inflammation; Others

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Cancer; Infection; Inflammation/Immunology

• Solubility :

  10 mM in DMSO

• Smiles :

  NC1=NC2=CC=CC=C2C3=C1N=CN3C([2H])([2H])C([2H])(C([2H])([2H])[2H])C([2H])([2H])[2H]

• Molecular Formula :

  C14H7D9N4

• Molecular Weight :

  249.36

• Precautions :

  P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

• References & Citations :

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Aditya K Gupta, et al. Imiquimod: a review. J Cutan Med Surg. Nov-Dec 2002;6 (6) :554-60.|[3]Athina Angelopoulou, et al. Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19. Environ Res. 2020 Sep; 188: 109858.|[4]Michael P Schön, et al. The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion. J Invest Dermatol. 2006 Jun;126 (6) :1338-47.|[5]Yuji Kan, et al. Imiquimod suppresses propagation of herpes simplex virus 1 by upregulation of cystatin A via the adenosine receptor A1 pathway. J Virol. 2012 Oct;86 (19) :10338-46.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Isotope-Labeled Compounds

• Clinical Information :

  No Development Reported